 OncLive | Small-Molecule Inhibitors Hold Promise for Elderly CLL Patients OncLive Wierda noted that a phase II study is currently under way for patients ≥65 years with previously untreated CLL who will receive GS-1101 in combination with rituximab versus placebo plus rituximab. The GS-1101 dosage being evaluated is 150 mg twice ... |
